A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
PTC THERAPEUTICS, INC.
PTCT
$674M
Mkt Cap
$76.82
-2.08%
PTC THERAPEUTICS, INC. (PTCT) has a current P/E ratio of 9.9, compared to its historical median P/E of 10.1. The stock is currently considered Cheap based on its historical valuation range.
PTC THERAPEUTICS, INC. (PTCT) has a 5-year average return on invested capital (ROIC) of -24.5%. This is below average and may indicate limited pricing power.
PTC THERAPEUTICS, INC. (PTCT) has a market capitalization of $6.4B. It is classified as a mid-cap stock.
PTC THERAPEUTICS, INC. (PTCT) does not currently pay a regular dividend.
Based on historical P/E analysis, PTC THERAPEUTICS, INC. (PTCT) appears cheap. The current P/E of 9.9 is 2% below its historical median of 10.1.
PTC THERAPEUTICS, INC. (PTCT) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
PTC THERAPEUTICS, INC. (PTCT) reported annual revenue of $1.7 billion in its most recent fiscal year, based on SEC EDGAR filings.
PTC THERAPEUTICS, INC. operates in the Pharmaceutical Preparations industry, Healthcare sector. Full business description from SEC filing not yet available.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 827M | 1.7B | 807M | 938M | 699M | 539M |
| Net Income | -187M | 683M | -363M | -627M | -559M | -524M |
| EPS | $-2.31 | $77.80 | $-47.30 | $-83.70 | $-77.90 | $-74.30 |
| Free Cash Flow | -226M | 702M | -114M | -187M | -389M | -280M |
| ROIC | -1.6% | 36.9% | -17.7% | -23.2% | -20.7% | -97.5% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | -3.31 | -0.34 | -0.49 | -1.97 | 356.28 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -58M | 867M | -303M | -440M | -447M | -374M |
| Operating Margin | -7.1% | 50.1% | -37.5% | -46.9% | -64.0% | -69.5% |
| ROE | 0.0% | -104.7% | 37.9% | 107.5% | 323.5% | -216.7% |
| Shares Outstanding | 83M | 9M | 8M | 7M | 7M | 7M |
| Metric | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | N/A | N/A | 83M | 194M | 265M | 307M | 381M | 539M | 699M | 938M | 807M | 1.7B | 827M |
| Gross Margin | N/A | N/A | 100.0% | 97.6% | 95.2% | 96.0% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | 80M | 122M | 118M | 117M | 172M | 257M | 478M | 541M | 651M | 667M | 534M | 455M | 447M |
| SG&A | 45M | 82M | 97M | 121M | 154M | 203M | 245M | 286M | 326M | 333M | 301M | 347M | 352M |
| EBIT | -99M | -167M | -132M | -64M | -116M | -241M | -432M | -374M | -447M | -440M | -303M | 867M | -58M |
| Op. Margin | N/A | N/A | -159.7% | -33.1% | -43.7% | -78.6% | -113.4% | -69.5% | -64.0% | -46.9% | -37.5% | 50.1% | -7.1% |
| Net Income | -94M | -170M | -142M | -79M | -128M | -252M | -438M | -524M | -559M | -627M | -363M | 683M | -187M |
| Net Margin | N/A | N/A | -171.8% | -40.6% | -48.4% | -82.0% | -115.1% | -97.3% | -80.0% | -66.8% | -45.0% | 39.4% | -22.6% |
| Non-Recurring | 0 | 37K | 0 | -5K | -2K | -312K | -16K | 0 | -80K | -806K | -4.3M | -130K | -130K |
| Returns on Capital | |||||||||||||
| ROIC | -42.6% | -55.3% | -53.1% | -30.4% | -32.3% | -36.5% | -52.2% | -97.5% | -20.7% | -23.2% | -17.7% | 36.9% | -1.6% |
| ROE | -43.1% | -65.0% | -82.2% | -57.2% | -50.5% | -53.2% | -81.4% | -216.7% | 323.5% | 107.5% | 37.9% | -104.7% | 0.0% |
| ROA | -38.7% | -48.8% | -44.8% | -23.9% | -17.0% | -18.3% | -22.9% | -25.3% | -30.7% | -34.8% | -20.2% | 29.7% | -6.5% |
| Cash Flow | |||||||||||||
| Op. Cash Flow | -57M | -124M | -104M | -10M | -28M | -99M | -194M | -251M | -357M | -158M | -108M | 711M | -218M |
| Free Cash Flow | -62M | -127M | -105M | -13M | -35M | -112M | -212M | -280M | -389M | -187M | -114M | 702M | -226M |
| Owner Earnings | -79M | -161M | -142M | -58M | -87M | -173M | -308M | -419M | -596M | -497M | -258M | 598M | -345M |
| CapEx | 4.7M | 2.7M | 1.8M | 3.1M | 7.1M | 14M | 18M | 28M | 32M | 28M | 6.5M | 8.9M | 8.3M |
| Maint. CapEx | 2.2M | 2.9M | 3.3M | 18M | 26M | 32M | 43M | 64M | 129M | 237M | 76M | 39M | 47M |
| Growth CapEx | 2.4M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| D&A | 2.2M | 2.9M | 3.3M | 18M | 26M | 32M | 43M | 64M | 129M | 237M | 76M | 39M | 47M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 1.2% | 0.0% |
| Capital Allocation | |||||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 19M | 34M | 35M | 31M | 33M | 42M | 70M | 104M | 110M | 102M | 75M | 75M | 80M |
| Debt Repayment | 49K | 0 | 0 | 432K | 0 | 0 | 28M | 0 | 150M | 82M | 0 | 0 | 0 |
| Balance Sheet | |||||||||||||
| Net Debt | -315M | -247M | -133M | -46M | -75M | -359M | -706M | -261M | 274M | -479M | -766M | -1.3B | -1.3B |
| Cash & Equiv. | 50M | 58M | 58M | 112M | 169M | 288M | 209M | 190M | 280M | 594M | 780M | 985M | 1.9B |
| Long-Term Debt | 49K | 92M | 98M | 145M | 141M | 294M | 309M | 282M | 572M | 284M | 285M | 287M | 287M |
| Debt/Equity | 0.00 | 0.41 | 0.82 | 0.93 | 0.44 | 0.55 | 0.82 | 356.28 | -1.97 | -0.49 | -0.34 | -3.31 | 0.00 |
| Interest Coverage | -99413.0 | N/A | -29.3 | -10.3 | -14.9 | -31.3 | -44.0 | -39.1 | -24.2 | -12.2 | -52.0 | 152.0 | 152.0 |
| Equity | 298M | 226M | 120M | 156M | 351M | 594M | 482M | 1.4M | -347M | -819M | -1.1B | -205M | -180M |
| Total Assets | 333M | 365M | 269M | 392M | 1.1B | 1.6B | 2.2B | 1.9B | 1.7B | 1.9B | 1.7B | 2.9B | 2.9B |
| Total Liabilities | 35M | 139M | 150M | 235M | 768M | 1.0B | 1.7B | 1.9B | 2.1B | 2.7B | 2.8B | 3.1B | 3.0B |
| Intangibles | N/A | N/A | 0 | 133M | 701M | 711M | 715M | 725M | 706M | 379M | 119M | 389M | 381M |
| Retained Earnings | -423M | -593M | -735M | -814M | -939M | -1.2B | -1.6B | -2.1B | -2.7B | -3.3B | -3.6B | -3.0B | -3.0B |
| Working Capital | 291M | 311M | 212M | 167M | 154M | 543M | 954M | 445M | 288M | 616M | 785M | 1.3B | 1.3B |
| Current Assets | 324M | 356M | 261M | 249M | 321M | 779M | 1.2B | 954M | 694M | 1.2B | 1.4B | 2.3B | 2.3B |
| Current Liabilities | 32M | 45M | 50M | 82M | 167M | 236M | 277M | 509M | 406M | 603M | 581M | 968M | 924M |
| Per Share Data | |||||||||||||
| EPS | -29.70 | -50.70 | -41.70 | -20.20 | -27.50 | -42.70 | -66.40 | -74.30 | -77.90 | -83.70 | -47.30 | 77.80 | -2.31 |
| Owner EPS | -24.97 | -47.95 | -41.63 | -14.91 | -18.68 | -29.36 | -46.66 | -59.42 | -83.03 | -66.34 | -33.59 | 68.13 | -4.16 |
| Book Value | 94.55 | 67.22 | 35.09 | 40.00 | 75.30 | 100.88 | 73.04 | 0.20 | -48.37 | -109.34 | -142.97 | -23.40 | -2.18 |
| Cash Flow/Share | -18.14 | -36.98 | -30.39 | -2.57 | -5.93 | -16.74 | -29.41 | -35.64 | -49.70 | -21.16 | -14.02 | 81.05 | -1.69 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 3.2M | 3.4M | 3.4M | 3.9M | 4.7M | 5.9M | 6.6M | 7.1M | 7.2M | 7.5M | 7.7M | 8.8M | 82.9M |
| Valuation | |||||||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 10.1 | -33.3 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 1.0 | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 6.7 | N/A |
| Price/Book | 5.6 | 4.8 | 3.3 | 4.2 | 4.3 | 4.8 | 8.8 | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Sales | N/A | N/A | 4.5 | 3.1 | 5.9 | 7.6 | 9.0 | 6.0 | 4.2 | 3.1 | 3.2 | 2.8 | 7.7 |
| FCF Yield | -3.7% | -11.6% | -27.0% | -2.0% | -2.3% | -3.9% | -5.0% | -9.8% | -15.1% | -8.7% | -3.3% | 10.2% | -3.6% |
| Market Cap | 1.7B | 1.1B | 390M | 654M | 1.5B | 2.9B | 4.2B | 2.9B | 2.6B | 2.1B | 3.5B | 6.9B | 6.4B |
| Avg. Price | 30.61 | 47.93 | 11.01 | 15.47 | 33.38 | 39.73 | 51.79 | 45.57 | 41.12 | 38.63 | 34.13 | 55.35 | 76.82 |
| Year-End Price | 53.37 | 32.45 | 11.43 | 16.71 | 32.01 | 48.81 | 64.13 | 40.42 | 35.77 | 28.58 | 45.23 | 78.56 | 76.82 |
PTC THERAPEUTICS, INC. passes 2 of 9 quality checks, indicating weak fundamentals.
PTC THERAPEUTICS, INC. trades at 9.9x trailing earnings, compared to its 15-year median P/E of 10.1x, suggesting it is currently Cheap relative to its historical range. On a free-cash-flow basis, the stock trades at 9.1x vs a median of 1.0x.
PTC THERAPEUTICS, INC. (PTCT) has a net profit margin of 39.4%. This is a strong margin indicating high profitability.
PTC THERAPEUTICS, INC. (PTCT) generated $702 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
PTC THERAPEUTICS, INC. (PTCT) reported earnings per share (EPS) of $77.80 in its most recent fiscal year.
PTC THERAPEUTICS, INC. (PTCT) has a return on equity (ROE) of -104.7%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 15 years of financial data for PTC THERAPEUTICS, INC. (PTCT), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
PTC THERAPEUTICS, INC. (PTCT) has a book value per share of $-23.40, based on its most recent annual SEC filing.